➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Amylamine

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Amylamine?

Amylamine is an investigational drug.

There have been 20 clinical trials for Amylamine. The most recent clinical trial was a Phase 3 trial, which was initiated on April 18th 2019.

The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are CoMentis, Yale University, and Targacept Inc.

There is one US patent protecting this investigational drug and twenty international patents.

Recent Clinical Trials for Amylamine
Cholinergic Mechanisms of Attention in AgingVanderbilt University Medical CenterEarly Phase 1
Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar HyperhidrosisAtacama TherapeuticsPhase 2
Pilot Study of Mecamylamine for Autonomic Dysreflexia ProphylaxisWayne State UniversityPhase 4

See all Amylamine clinical trials

Clinical Trial Summary for Amylamine

Top disease conditions for Amylamine
Top clinical trial sponsors for Amylamine

See all Amylamine clinical trials

US Patents for Amylamine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Amylamine   Get Started Free Electrically conductive adhesives comprising at least one metal precursor HENKEL AG & CO. KGAA (Duesseldorf, DE)   Get Started Free
Amylamine   Get Started Free Coating methods using organosilica materials and uses thereof EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (Annandale, NJ)   Get Started Free
Amylamine   Get Started Free Ink jet recording method Seiko Epson Corporation (JP)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Amylamine

Drugname Country Document Number Estimated Expiration Related US Patent
Amylamine China CN103347974 2031-02-11   Get Started Free
Amylamine European Patent Office EP2487215 2031-02-11   Get Started Free
Amylamine European Patent Office EP2673330 2031-02-11   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.